NasdaqGM:ADMABiotechs
ADMA Biologics CEO Trading Plan Sparks Questions On Valuation Gap
ADMA Biologics CEO Adam Grossman executed a pre-arranged sale of company shares.
The transaction also involved the exercise of previously granted stock options.
The activity represents insider trading carried out under an established trading plan.
For investors watching ADMA Biologics, ticker NasdaqGM:ADMA, this insider activity comes with the stock last closing at $15.95. The company’s long term track record includes very large returns over 3 and 5 years, while the 1 year return is close...